International Scholarly Research Notices / 2012 / Article / Tab 1

Clinical Study

Evaluation of Acute Locoregional Toxicity in Patients with Breast Cancer Treated with Adjuvant Radiotherapy in Combination with Pazopanib

Table 1

Patient characteristics.

ArmLateralitySTAGECHEMOConcurrent SITERT Fields RT DOSE

P-RTRIIIAC-T + PPCW + Sclav36000
P-RTLIIIAC-T + PPCW + Sclav36000
P-RTLIIIAC-T + PPCW + Sclav36000
P-RTRIIIAC-T + PPIntact26000
P-RTRIIIAC-T + PPIntact + Sclav36000
P-RTRIIIAC-T + PPCW + Sclav36000
P-RTLIIIAC-T + P + HP + HerceptinIntact + Sclav + IM36600
P-RTRIIIAC-T + PPIntact + Sclav36000
P-RTLIIIAC-T + P + HP + HerceptinCW + Sclav36000
P-RTLIIIAC-T + PPCW + Sclav36040
P-RTLIIIAC-T + PPCW + Sclav and axilla46000
P-RTLIIIAC-T + PPCW + Sclav36000
RTRIVAC-T//CW + Sclav36600
RTLIIIAC-T + HHerceptinCW + Sclav35800
RTLIIIAC-T + HHerceptinCW + Sclav36000
RTRIIIAC-T//Intact + Sclav, IM, PAB/AAB5 6000
RTRIIIAC-T//Intact + Sclav36000
RTLIIITC, TAC//CW + Sclav36000
RTLIIIAC-T + HHerceptinCW + Sclav36000
RTLIIITC + HHerceptinCW + Sclav36000
RTLIIIAC-T + HHerceptinCW + Sclav36000
RTLIII////CW26600
RTRIIIAC-T//Intact36000
RTLIIITC + HHerceptinCW + Sclav36000
RTLIIIAC//CW + Sclav36000
RTLIIIAC-T//CW + Sclav36000
RTLIII////CW + Sclav36000
RTLIIITC + HHerceptinCW + Sclav36000
RTRIII////Intact + Sclav36000
RTRIIIECF//CW + Sclav36000
RTLIIIAC-T + HHerceptinCW + Sclav36000
RTRIIIAC-T//Intact + Sclav36000
RTRIIIAC-T//Intact + Sclav36000
RTRIIITC, TAC//CW + Sclav36000
RTLIIIAC-T + HHerceptinCW + Sclav36000
RTLIIITC + HHerceptinCW + Sclav36000
RTLIIIAC-T + HHerceptinCW + Sclav36000

Abbreviations: P: pazopanib; RT: radiotherapy; L: left; R: right; A: adriamycin; C: cytoxan; T: taxotere; H: herceptin; CW: chest wall; Sclav: supraclavicular; IM: internal mammary; PAB: posterior axillary boost; AAB: anterior axillary boost.